Welcome to the weekly HLTH newsletter, your curated lens into healthcare innovation. Each week, we spotlight the trends, breakthroughs, and conversations you can’t afford to miss.
Top Story
Money talks, and in June, it screamed transformation. Sword Health, Abridge, and 23andMe didn’t just make headlines—they lit up the health tech landscape with bold bets and billion-dollar valuations.
Is AI finally proving its worth in clinical care? Can a nonprofit really “rescue” sensitive genetic data from corporate hands? And why are payers so obsessed with documentation tools? The answers say more about the future of healthcare than the dollar amounts ever could.
Don’t just read the numbers—understand what they mean. Discover why the smartest capital is flowing toward outcomes, intelligence, and privacy.
500 million people worldwide are living with diabetes—and that number is rising. In Get In Sync with Your Glucose, Dexcom Warriors Lance Bass, Kesha Carter, and Jake Leach share personal journeys and powerful insights into how glucose biosensors are reshaping chronic care. This conversation, moderated by Axios’ Tina Reed, dives into the life-changing potential of biosensing tech and what’s at stake if innovation stalls.
Interested in sponsoringHLTH USA 2025?Get in touch!
Hot Off the Press
Meet the First 50+ Voices Shaping the Future of Health
The stage is set. HLTH USA 2025 is bringing together the changemakers redefining health, tech, wellness, investment, and care delivery. Headliners include: Sophia Bush (Investor & Actress), Greg A. Adams (CEO, Kaiser Permanente), and Bret Taylor (CEO, Sierra), to name a few. And that’s just the beginning.
Explore the growing speaker lineup for HLTH USA, October 19–22 in Las Vegas. 👉
Healthcare is crossing the threshold from automation to agency. At the AI Vizionaries Summit, leaders didn’t just discuss AI’s future—they unveiled a new paradigm: agentic AI, where algorithms don’t wait for prompts—they act, decide, and transform care at the source.
But as AI tools mature from pilots to platforms, a bigger question looms: can pharma scale with this new infrastructure, or will it be left behind? In our latest white paper discover what’s driving this revolution—and where the next battle lines are being drawn.
